Pharmaceuticals 2009, 2(3), 150-167; doi:10.3390/ph2030150
Review

Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies

Russell H. Swerdlowemail
Departments of Neurology and Molecular and Integrative Physiology, University of Kansas School of Medicine, Kansas City, MO, Kansas 66160, USA
Received: 19 November 2009; in revised form: 27 November 2009 / Accepted: 2 December 2009 / Published: 3 December 2009
(This article belongs to the Special Issue Mitochondrial Drugs for Neurodegenerative Diseases)
PDF Full-text Download PDF Full-Text [328 KB, uploaded 3 December 2009 09:34 CET]
Abstract: Neurodegenerative diseases are a common late-life scourge for which diseasemodifying treatments are sorely needed. Mitochondrial perturbation is commonly observed in these diseases, so pursuing treatment development strategies that target mitochondria or processes affected by mitochondria seems reasonable. This review discusses the rationale underlying past and current efforts to treat neurodegenerative diseases using mitochondrial medicine, and tries to predict how future efforts might proceed.
Keywords: mitochondria; mitochondrial biogenesis; mitochondriopathies; neurodegenerative diseases; oxidative stress

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Swerdlow, R.H. Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals 2009, 2, 150-167.

AMA Style

Swerdlow RH. Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals. 2009; 2(3):150-167.

Chicago/Turabian Style

Swerdlow, Russell H. 2009. "Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies." Pharmaceuticals 2, no. 3: 150-167.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert